Akari Therapeutics PLC AKTX
9.76
(0.30)
(2.98%)
as of 25 Sep
- Market cap
- $17.6M
- P/E
- 0.0×
Follow AKTX
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.19 | 0.44 | 0.27 | 0.60 |
Net Debt/EBITDA |
0.25 | 1.42 | 0.18 | 1.53 | |
Debt/Assets |
1.46% | 1.41% | 0.00% | 1.79% | |
Debt/Equity |
0.03 | 0.02 | 0.00 | 0.04 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.33 | 0.57 | 0.17 | 0.65 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.94 | 0.89 | 0.89 | 0.78 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(2.60) | (3.61) | (1.68) | (1.74) | |
Cash per Share |
3.12 | 6.25 | 1.91 | 4.33 | |
Shareholders Equity per Share |
27.78 | 33.66 | 9.69 | 10.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
27.78 | 33.66 | 9.69 | 10.38 | |
Free Cash Flow |
(2.12) | (3.04) | (2.49) | (3.11) | |
Working Capital |
(12.62) | (6.89) | (9.83) | (5.61) | |
Net Current Asset Value |
(19.74) | (14.10) | (15.92) | (11.70) | |
| Other line items | |||||
Quick Ratio |
0.16 | 0.43 | 0.21 | 0.56 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.60) | (3.61) | (1.68) | (1.74) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
7.81 | 10.59 | 10.85 | 10.50 | |
Average Assets |
24.06 | 49.23 | 42.42 | 44.77 | |
Average Common Equity |
8.00 | 25.28 | 18.06 | 22.10 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates